Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen

Nirav N. Shah, Aniko Szabo, Raya Saba, Lauren Strelec, Dheeraj Kodali, John L. Vaughn, Olukemi Esan, David T. Yang, Anthony R. Mato, Abraham S. Kanate, Horatiu Olteanu, Mehdi Hamadani, Timothy S. Fenske, Vaishalee P. Kenkre, Jakub Svoboda, Amanda F. Cashen, Narendranath Epperla

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Grade 3A follicular lymphoma (FL) is a heterogenous disease with multiple frontline treatment regimens. We performed a multicenter retrospective analysis to evaluate the efficacy of various frontline regimens for grade 3A FL. Although anthracycline-based therapy was superior to the combination of chemotherapy with cyclophosphamide, vincristine, and prednisone for grade 3A FL, clinical outcomes, including survival, were similar compared to bendamustine-based treatment.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number2
DOIs
StatePublished - Feb 2019

    Fingerprint

Keywords

  • Chemotherapy
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Shah, N. N., Szabo, A., Saba, R., Strelec, L., Kodali, D., Vaughn, J. L., Esan, O., Yang, D. T., Mato, A. R., Kanate, A. S., Olteanu, H., Hamadani, M., Fenske, T. S., Kenkre, V. P., Svoboda, J., Cashen, A. F., & Epperla, N. (2019). Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clinical Lymphoma, Myeloma and Leukemia, 19(2), 95-102. https://doi.org/10.1016/j.clml.2018.11.010